[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Watanabe T, Fuse T, Umezu M, Yamamoto M, Demura K, Niwa Y: Radiation-induced osteosarcoma 16 years after surgery and radiation for glioma--case report. Neurol Med Chir (Tokyo); 2006 Jan;46(1):51-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 35-year-old man developed osteosarcoma of the left parietal and occipital bones 16 years after radiotherapy for glioma in the right occipital lobe.
  • Radiotherapy of the primary neoplasm used 50 Gy administered to a localized field through two lateral ports.
  • The secondary neoplasm arose contralateral to the primary lesion but within the irradiated field.
  • The tumor had a multilocular cyst with considerable intracranial extension, and symptoms of elevated intracranial pressure were prominent early in the course.
  • After a short-lived initial remission following surgical intervention and chemotherapy, the patient deteriorated because of tumor recurrence and died 18 months after the diagnosis.
  • Radiation-induced osteosarcoma is a well-known but rare complication of radiotherapy for brain neoplasms with a poor prognosis.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Glioma / radiotherapy. Neoplasms, Radiation-Induced / etiology. Occipital Bone. Osteosarcoma / etiology. Parietal Bone. Skull Neoplasms / etiology
  • [MeSH-minor] Adult. Humans. Male. Radiotherapy / adverse effects. Time Factors

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16434828.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


2. Barut F, Kandemir NO, Ozdamar SO, Gul S, Bektas S, Gun BD, Bahadir B: Gliosarcoma with chondroblastic osteosarcomatous differentation: report of two case with clinicopathologic and immunohistochemical features. Turk Neurosurg; 2009 Oct;19(4):417-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliosarcoma is a rare tumor of the central nervous system characterized by a biphasic histological pattern.
  • CASE 1: A 52- year-old male patient underwent parietal craniotomy due to anaplastic ependymoma.
  • The case had radiotherapy and chemotherapy postoperatively.
  • After the first operation, additional resections were performed for tumor because of recurrences at the fourth, seventh and tenth months.
  • The patient died after the last tumor resection.
  • Histopathologic examination of the postmortem biopsy revealed neoplasm displaying a biphasic morphologic pattern including both gliomatous and sarcomatous components.
  • CASE 2: The case was a 69-year-old male patient with a right frontal lobe mass histologically diagnosed as gliosarcoma displaying sarcomatous and glial components.
  • We report two cases with an extremely rare histopathological diagnosis of "gliosarcoma with features of chondroblastic osteosarcoma".
  • [MeSH-major] Brain Neoplasms / pathology. Chondroblastoma / pathology. Gliosarcoma / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Aged. Biopsy. Cell Differentiation. Ependymoma / pathology. Ependymoma / surgery. Fatal Outcome. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / pathology

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19847765.001).
  • [ISSN] 1019-5149
  • [Journal-full-title] Turkish neurosurgery
  • [ISO-abbreviation] Turk Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


3. Hueser CN, Nguyen NC, Osman M, Havlioglu N, Patel AJ: Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans. World J Surg Oncol; 2008;6:102
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extrapulmonary small cell carcinoma: involvement of the brain without evidence of extracranial malignancy by serial PET/CT scans.
  • BACKGROUND: Extrapulmonary small cell carcinoma (EPSCC) involving the brain is a rare manifestation of an uncommon tumor type.
  • CASE PRESENTATION: We report a 59 year-old Caucasian female diagnosed with an EPSCC involving the left parietal lobe without detectable extracranial primary tumor followed by serial positron emission tomography/computed tomography (PET/CT) imaging.
  • Serial PET/CT scans of the entire body failed to reveal any extracranial [18F]2-fluoro-2-deoxy-D-glucose (FDG) avid lesions at either diagnosis or follow-up.
  • CONCLUSION: Chemotherapy may show a transient response in the treatment of EPSCC.
  • Further studies are needed to help identify optimal treatment strategies.
  • [MeSH-major] Brain Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Craniotomy. Female. Fluorodeoxyglucose F18. Humans. Middle Aged. Radiopharmaceuticals. Topotecan / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Nov 1;107(9):2262-9 [16998932.001]
  • [Cites] Recent Results Cancer Res. 2008;170:193-202 [18019627.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1194-204 [17962613.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):39-42 [17270664.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):30-8 [17270663.001]
  • [Cites] Semin Oncol. 2007 Feb;34(1):1-2 [17270659.001]
  • [Cites] J Nucl Med. 2007 Jan;48 Suppl 1:78S-88S [17204723.001]
  • [Cites] Ann Oncol. 2006 May;17 Suppl 5:v99-102 [16807475.001]
  • [Cites] J Korean Med Sci. 2006 Oct;21(5):833-7 [17043415.001]
  • [Cites] Neth J Med. 2000 Feb;56(2):51-5 [10710941.001]
  • [Cites] Mod Pathol. 2000 Mar;13(3):238-42 [10757334.001]
  • [Cites] Histopathology. 2000 May;36(5):415-20 [10792482.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1217-23 [10976695.001]
  • [Cites] Annu Rev Med. 2002;53:89-112 [11818465.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):1911-7 [14660716.001]
  • [Cites] Jpn J Clin Oncol. 2004 May;34(5):250-4 [15231859.001]
  • [Cites] Ann Diagn Pathol. 2006 Apr;10(2):67-71 [16546039.001]
  • [Cites] South Med J. 2005 Mar;98(3):345-9 [15813162.001]
  • [Cites] Radiology. 2005 Jan;234(1):227-34 [15564390.001]
  • [Cites] Med Oncol. 1998 Apr;15(1):66-9 [9643534.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] Cancer. 1997 May 1;79(9):1729-36 [9128989.001]
  • [Cites] Ann Oncol. 1994 Dec;5(10):909-13 [7696162.001]
  • [Cites] Cancer. 1990 Feb 1;65(3):422-4 [1688727.001]
  • [Cites] Medicine (Baltimore). 1987 Nov;66(6):457-71 [2824968.001]
  • (PMID = 18817561.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ PMC2564932
  •  go-up   go-down


Advertisement
4. Sands S, Van Gorp WG, Finlay JL: A dramatic loss of non-verbal intelligence following a right parietal ependymoma: brief case report. Psychooncology; 2000 May-Jun;9(3):259-66
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dramatic loss of non-verbal intelligence following a right parietal ependymoma: brief case report.
  • Virtually all reports on the effects of focal brain lesions upon specific neuropsychological functions are based upon estimates of cognitive loss in persons following a lesion, without proof of premorbid capacity.
  • This report presents the case of a 19-year-old left-handed male with assessment of Verbal and Performance I.Q. testing 1 year prior to a subsequent brain tumor for reasons unrelated to the neoplasm.
  • The patient was then re-tested 23 months later, following the diagnosis and treatment of a supratentorial ependymoma in the right parietal region.
  • His multi-modal treatment regimen included a partial surgical resection of the tumor, cranio-spinal irradiation with focal boost to the primary site, and chemotherapy.
  • These findings clearly document the important cognitive functions associated with the right parietal lobe.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / surgery. Cognition Disorders / etiology. Ependymoma / complications. Ependymoma / therapy. Parietal Lobe / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Wechsler Scales

  • Genetic Alliance. consumer health - Ependymoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 John Wiley & Sons, Ltd.
  • (PMID = 10871722.001).
  • [ISSN] 1057-9249
  • [Journal-full-title] Psycho-oncology
  • [ISO-abbreviation] Psychooncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Rhines LD, Sampath P, DiMeco F, Lawson HC, Tyler BM, Hanes J, Olivi A, Brem H: Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma. Neurosurgery; 2003 Apr;52(4):872-9; discussion 879-80
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
  • OBJECTIVE: Local delivery of carmustine (BCNU) from biodegradable polymers prolongs survival against experimental brain tumors.
  • Moreover, paracrine administration of interleukin-2 (IL-2) has been shown to elicit a potent antitumor immune response and to improve survival in animal brain tumor models.
  • We demonstrate both in vitro release of cytokine from the microspheres and histological evidence of the inflammatory response elicited by IL-2 released from the microspheres in the rat brain.
  • Five days later, animals in each group were randomized to receive polymer implants loaded with 0, 3.8, or 10% BCNU at the tumor site.
  • CONCLUSION: By showing synergy of IL-2 and BCNU in an animal glioma model and using a reproducible synthetic delivery system for each agent (i.e., one that did not rely on genetically engineered cells or viruses), we hope that the combination of local immunotherapy and chemotherapy can take an important step closer to clinical application in patients with malignant brain tumors.
  • [MeSH-major] Brain Neoplasms / drug therapy. Carmustine / administration & dosage. Gliosarcoma / drug therapy. Interleukin-2 / administration & dosage. Parietal Lobe
  • [MeSH-minor] Animals. Biodegradation, Environmental. Biological Availability. Chondroitin Sulfates. Female. Gelatin. Injections, Intralesional. Microspheres. Neoplasm Transplantation. Polymers. Rats. Rats, Inbred F344. Stereotaxic Techniques. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. GELATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12657184.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01-CA 52857
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-2; 0 / Polymers; 9000-70-8 / Gelatin; 9007-28-7 / Chondroitin Sulfates; U68WG3173Y / Carmustine
  •  go-up   go-down


6. Arai A, Taomoto K, Yokoyama M, Kudo H, Nishisaki H, Kajimoto K: [A case of CNS metastasis from gastric MALT lymphoma]. No Shinkei Geka; 2009 Dec;37(12):1235-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 53-year-old man who presented with CNS metastasis from gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
  • The symptoms at the time of diagnosis were dizziness and aphasia.
  • MRI revealed a left parietal lobe tumor with a large peritumoral edema.
  • Eradication of Helicobacter pylori led to remission of the disease 18 months after the treatment.
  • From his past history, the brain tumor was suspected of being a metastatic lymphoma.
  • Histopathological findings including lymphocytic subsets were almost identical between the primary gastric MALT lymphoma and metastatic brain lymphoma.
  • Complete remission was obtained by repeated high-dose methotrexate chemotherapy.
  • There has been no recurrence for 5 years without additional therapy.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999557.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Guenther PP, Huebner A, Sobottka SB, Neumeister V, Weissbach G, Todt H, Parwaresch R: Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy. J Pediatr Hematol Oncol; 2001 Feb;23(2):134-8
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.
  • An 8-year-old girl with an isolated cerebral mast cell tumor is presented.
  • Specific histopathologic stains were used to confirm the diagnosis detecting immunophenotype and proliferative activity.
  • Treatment with irradiation, intrathecal cytarabine, and interferon-alpha2b did not induce regression whereas polychemotherapy did.
  • Systemic combination chemotherapy led to marked transient tumor regression in this proliferating mast cell sarcoma in an unusual intracranial location.
  • [MeSH-major] Mast-Cell Sarcoma / drug therapy. Parietal Lobe / pathology. Supratentorial Neoplasms / drug therapy. Temporal Lobe / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Daunorubicin / administration & dosage. Disease Progression. Etoposide / administration & dosage. Fatal Outcome. Female. Headache / etiology. Humans. Immunologic Factors / therapeutic use. Injections, Spinal. Interferon-alpha / therapeutic use. Nausea / etiology. Neoplasm Recurrence, Local. Palliative Care. Papilledema / etiology. Prednisolone / administration & dosage. Radioisotope Teletherapy. Recombinant Proteins. Remission Induction. Treatment Failure. Vomiting / etiology

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11216707.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Recombinant Proteins; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; 99210-65-8 / interferon alfa-2b; 9PHQ9Y1OLM / Prednisolone; ZS7284E0ZP / Daunorubicin; DAV regimen
  •  go-up   go-down


8. Matsuda R, Motoyama Y, Takeshima Y, Kimura R, Iida J, Nakamura M, Mishima H, Park YS, Hirabayashi H, Nakase H, Sakai T: [A case of brain metastasis of renal pelvic carcinoma]. No Shinkei Geka; 2009 Feb;37(2):179-82
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of brain metastasis of renal pelvic carcinoma].
  • Contrast-enhanced computed tomography (CT) revealed renal tumor and multiple lung metastases.
  • After nephroureterectomy, combination chemotherapy consisting of methotrexate, doxorubicin and cisplatin was performed.
  • Contrast-enhanced CT of the head revealed a heterogeneous enhancement tumor in the parietal lobe.
  • Surgical resection was performed by right parietal craniotomy.
  • Because the tumor was invasive in the superior sagittal sinus, subtotal removal of the tumor was performed.
  • She returned to ordinary life, but 7 months later tumor recurrence took place.
  • Repeated surgical resection and stereotactic radiosurgery was performed, but she died 44 months after the initial nephroureterectomy due to the relapse of brain metastasis.
  • Brain metastasis of renal pelvic carcinoma is extremely rare, and we have found only three case reports.
  • We describe the course of our patient, and review the three cases of brain metastasis of renal pelvic carcinoma that are in the literature.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology. Kidney Pelvis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227160.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


9. Beaumont TL, Kupsky WJ, Barger GR, Sloan AE: Gliosarcoma with multiple extracranial metastases: case report and review of the literature. J Neurooncol; 2007 May;83(1):39-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliosarcoma is a rare malignant neoplasm of the central nervous system with a propensity for metastasis.
  • Here we describe the case of a 47-year-old man who developed pervasive extracranial metastases from a temporal gliosarcoma following radio- and chemotherapy for a primary glioblastoma.
  • The patient initially presented with progressively worsening headaches, left-sided weakness and numbness associated with right temporo-parietal mass for which he underwent craniotomy with stereotactic gross-total excision.
  • The patient initially declined chemotherapy.
  • The tumor recurred twice and the patient underwent re-operation and multiple courses of chemotherapy; histopathological diagnosis remained glioblastoma multiforme.
  • The histogenesis and the potential role of therapeutic irradiation in the development of gliosarcoma are briefly reviewed.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / secondary. Liver Neoplasms / secondary. Neoplasms, Second Primary. Splenic Neoplasms / secondary. Temporal Lobe. Thoracic Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Craniotomy. Fatal Outcome. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Stereotaxic Techniques

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1976 Oct;45(4):398-408 [956876.001]
  • [Cites] Cancer. 1969 Aug;24(2):270-6 [4307749.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2910-8 [7773942.001]
  • [Cites] Neuroradiology. 2001 Jul;43(7):555-8 [11512585.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3761-7 [9850019.001]
  • [Cites] Arch Pathol. 1972 Jan;93(1):26-31 [5006996.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1166-79 [9343324.001]
  • [Cites] Cancer. 1991 May 1;67(9):2342-9 [1849447.001]
  • [Cites] Acta Neuropathol. 1993;85(2):222-6 [8382897.001]
  • [Cites] Cancer. 1987 Apr 15;59(8):1506-8 [3545441.001]
  • [Cites] Pathology. 1984 Apr;16(2):217-21 [6087260.001]
  • [Cites] Clin Neuropathol. 2001 Sep-Oct;20(5):212-8 [11594506.001]
  • [Cites] Zentralbl Neurochir. 1980;41(1):57-68 [6258355.001]
  • [Cites] Surg Neurol. 1985 Dec;24(6):641-5 [2997942.001]
  • [Cites] Am J Pathol. 1955 Jul-Aug;31(4):633-53 [14388124.001]
  • [Cites] J Clin Oncol. 1999 May;17 (5):1516-25 [10334539.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):554-6 [2058514.001]
  • [Cites] Acta Neuropathol. 1996 Nov;92(5):515-9 [8922064.001]
  • [Cites] Neurosurgery. 1985 Sep;17(3):413-8 [4047352.001]
  • [Cites] Cancer. 1989 Feb 1;63(3):518-23 [2643455.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1510-8 [3476182.001]
  • [Cites] Acta Neuropathol. 1985;67(3-4):201-10 [4050334.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Sep;55(9):973-81 [8800093.001]
  • [Cites] J Neurosurg. 1984 Sep;61(3):599-601 [6747700.001]
  • [Cites] J Neurosurg. 1998 Sep;89(3):425-30 [9724117.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Sep;51(5):493-8 [1381414.001]
  • [Cites] Cancer. 1958 Sep-Oct;11(5):888-94 [13585341.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Acta Neuropathol. 1986;69(1-2):23-7 [3962596.001]
  • [Cites] Neurol Med Chir (Tokyo). 1989 Oct;29(10):938-43 [2482946.001]
  • [Cites] Acta Neuropathol. 1994;88(5):420-5 [7847070.001]
  • [Cites] Cancer. 1955 Jan-Feb;8(1):161-71 [13231048.001]
  • [Cites] Brain Pathol. 1999 Apr;9(2):421-2 [10219754.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Sep;54(5):651-6 [7666053.001]
  • [Cites] Ann Neurol. 1978 Sep;4(3):229-33 [214026.001]
  • [Cites] AMA Arch Pathol. 1958 Oct;66(4):536-49 [13582394.001]
  • [Cites] Surg Neurol. 2000 Nov;54(5):373-8; discusiion 378-9 [11165614.001]
  • (PMID = 17171442.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA101954
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


10. Grupka NL, Seinfeld J, Ryder J, Lillehei KO, Kleinschmidt-Demasters BK: Secondary central nervous system involvement by follicular lymphoma: case report and review of the literature. Surg Neurol; 2006 Jun;65(6):590-4
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: We report a patient with indolent stage IV follicular lymphoma, grade 1, initially successfully treated with chemotherapy, who later developed aggressive diffuse large B-cell lymphoma in the parieto-occipital lobe 8 years after initial presentation.
  • Although initial chemotherapy was successful, he developed several recurrences of lymphoma over the following years.
  • In May 2004, he presented with a discrete, single, massive parieto-occipital lobe brain lesion.
  • CONCLUSIONS: Parenchymal brain involvement, as opposed to dural or leptomeningeal, is a relatively uncommon pattern of spread to the CNS for systemic lymphomas.
  • More significantly, follicular lymphomas are one of the least frequent types of indolent lymphomas to develop clinically apparent, secondary CNS spread.
  • The presentation of an indolent follicular lymphoma with transformation to an aggressive diffuse large B-cell lymphoma within the brain parenchyma is rare.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Occipital Lobe / pathology. Parietal Lobe / pathology
  • [MeSH-minor] Antigens, CD / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16720183.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 16
  •  go-up   go-down


11. Yurdakul AS, Halilçolar H, Oztürk C, Tatar D, Karakaya J: [Factors affecting the prognosis in patients with primary lung cancer and brain metastases]. Tuberk Toraks; 2006;54(3):235-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Factors affecting the prognosis in patients with primary lung cancer and brain metastases].
  • Brain metastases are frequent features during the course of patients with lung carcinoma.
  • The aim of this study was to investigate prognostic factors for patients with brain metastasis from lung cancer.
  • Eighty-eight patients with brain metastasis from lung cancer were enrolled in the study.
  • Fifty-two (59.1%) patients had solitary brain metastasis and the most frequent metastasing site was parietal lobe (34.1%).
  • The median survival times were 3 months after diagnosis of lung carcinoma and 1.5 months after diagnosis of brain metastasis.
  • Although the absence of brain metastasis at the moment of diagnosis, metachronous metastasis, central localization of the tumour, chemotherapy administration and surgical treatment of brain metastasis are good prognostic factors affecting survival after the diagnosis of lung carcinoma, the positive factors affecting survival after brain metastasis are central localization of tumour, chemotherapy administration and surgical treatment of brain metastasis.
  • In conclusion, performing the combination of cranial radiotherapy, chemotherapy, surgical therapy and supporting therapy should be evaluated in all appropriate patients with brain metastasis from lung cancer.
  • [MeSH-major] Adenocarcinoma / mortality. Brain Neoplasms / mortality. Brain Neoplasms / secondary. Carcinoma, Small Cell / mortality. Carcinoma, Squamous Cell / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Turkey / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Brain Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001540.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


12. Ducray F, Colin P, Cartalat-Carel S, Pelissou-Guyotat I, Mahla K, Audra P, Gaucherand P, Honnorat J, Trouillas P: [Management of malignant gliomas diagnosed during pregnancy]. Rev Neurol (Paris); 2006 Mar;162(3):322-9
Hazardous Substances Data Bank. Fotemustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prise en charge des gliomes malins découverts au cours d'une grossesse.
  • In post-partum additional treatment with chemotherapy was started.
  • MRI showed an important left fronto-parietal lesion.
  • In post-partum additional treatment with radiotherapy and chemotherapy was started.
  • Two weeks after surgery the patient's neurological condition worsened and in agreement with the patient a therapeutic abortion was decided.
  • Afterwards additional treatment with radiotherapy and chemotherapy was started.
  • The last patient received combined treatment with radiotherapy and chemotherapy for local recurrence of a mesencephalic high-grade glioma.
  • A posteriori it was discovered that the patient was at 4 months' gestation during this treatment.
  • Their pregnancy should not prevent them from receiving the best treatment for their glioma.
  • Treatment will depend upon clinico-radiological presentation, histology, gestational age and the patient's desires.
  • After the first trimester of gestation this treatment can be given without any important risks for the child.
  • [MeSH-major] Case Management. Glioblastoma / therapy. Pregnancy Complications, Neoplastic / therapy. Supratentorial Neoplasms / therapy
  • [MeSH-minor] Abortion, Therapeutic. Adrenal Cortex Hormones / therapeutic use. Adult. Algorithms. Anesthesia, General. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carbamazepine / therapeutic use. Carmustine / administration & dosage. Cesarean Section. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Female. Frontal Lobe. Humans. Infant, Newborn. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local. Nitrosourea Compounds / administration & dosage. Nitrosourea Compounds / therapeutic use. Organophosphorus Compounds / administration & dosage. Organophosphorus Compounds / therapeutic use. Paresis / drug therapy. Paresis / etiology. Prednisolone / therapeutic use. Pregnancy. Prenatal Exposure Delayed Effects. Radiotherapy, Adjuvant. Remission Induction. Temporal Lobe

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol (Paris). 2006 Mar;162(3):293-4 [16585883.001]
  • (PMID = 16585887.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antineoplastic Agents; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 33CM23913M / Carbamazepine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9PHQ9Y1OLM / Prednisolone; GQ7JL9P5I2 / fotemustine; U68WG3173Y / Carmustine
  •  go-up   go-down


13. MacRae R, Grimard L, Hsu E, Nizalik E, Halton JM: Brain metastases in Wilms' tumor: case report and literature review. J Pediatr Hematol Oncol; 2002 Feb;24(2):149-53
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastases in Wilms' tumor: case report and literature review.
  • A 2-year-old girl who had a stage 2, favorable-histology Wilms tumor diagnosed when she was age 10 months presented with multiple brain metastases at second recurrence.
  • She had been treated with combined radiotherapy, surgery, and chemotherapy; at 2 months after treatment, recurrent disease developed in the central nervous system and she died.
  • Brain metastases are rare in the natural history of Wilms tumor.
  • Although it does not appear that cerebral metastases are a barrier to tumor eradication and long-term survival if treated with combined modality therapy, treatment should be individualized.
  • [MeSH-major] Brain Neoplasms / secondary. Frontal Lobe. Kidney Neoplasms. Occipital Lobe. Parietal Lobe. Wilms Tumor / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Craniotomy. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Infant. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / secondary. Mediastinal Neoplasms / surgery. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Nephrectomy. Palliative Care. Paresis / etiology. Thoracotomy

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11990704.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 25
  •  go-up   go-down


14. Udelnow A, Leinung S, Dannenberg C, Trantakis Ch, Schober R, Schönfelder M, Würl P: [A giant malignant tumour of the skull-Case report and differential diagnosis]. Zentralbl Chir; 2002 Mar;127(3):243-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A giant malignant tumour of the skull-Case report and differential diagnosis].
  • [Transliterated title] Ein gigantischer maligner Tumor der Kalotte - Fallbericht und Differentialdiagnose.
  • The case of a 72-year-old woman with a high-partially located tumor grown within a half year to a magnitude of 8.5 x 11 x 11 cm is reported.
  • The patient remembered a mastectomy and axillary lymphadenectomy followed by chemotherapy and radiation 8 years ago.
  • Searching for the pathohistological evaluation of the former breast tumor, a cystosarcoma phylloides malignum could be found out.
  • The tumor described here can be identified as a metastasis of this rare neoplasm.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / secondary. Skull Neoplasms / secondary
  • [MeSH-minor] Aged. Craniotomy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Parietal Lobe / pathology. Parietal Lobe / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11935491.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Fathi AR, Novoa E, El-Koussy M, Kappeler A, Mariani L, Vajtai I: Astroblastoma with rhabdoid features and favorable long-term outcome: report of a case with a 12-year follow-up. Pathol Res Pract; 2008;204(5):345-51
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Astroblastoma is a historically traded microscopic diagnosis to denote a rare neuroepithelial tumor of uncertain nosology, involving a distinctive pattern of pseudorosette arrangement of neoplastic cells.
  • While displaying some glial properties, the latter shall not - by definition - be either reducible to or part of any conventional glioma type.
  • We report on clinicopathologic correlations in a case of astroblastoma involving an extensive rhabdoid phenotype of tumor cells.
  • The male patient was operated on at the age of 53 and 59 years for a left parietal tumor measuring 5.8 cm in diameter at the first presentation.
  • The second surgery was complemented with radiotherapy of 66 Gy, followed by chemotherapy with Temozolomide.
  • Most tumor cells harbored paranuclear filamentous rhabdoid inclusions that were immunostained for vimentin and, in part, also for GFAP.
  • Involving a low-grade parent neoplasm, it also further substantiates the incipient perception that the rhabdoid phenotype neither is a peculiar but nonspecific convergence point of anaplastic evolution, nor are such lesions indiscriminately bound for a relentless course.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local. Neoplasms, Neuroepithelial / pathology. Parietal Lobe / pathology. Rhabdoid Tumor / pathology
  • [MeSH-minor] Antibodies, Antinuclear. Antibodies, Monoclonal. Antineoplastic Agents, Alkylating / therapeutic use. Cell Differentiation. Cerebral Angiography. Chemotherapy, Adjuvant. Craniotomy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Glial Fibrillary Acidic Protein / analysis. Humans. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Male. Middle Aged. Radiotherapy, Adjuvant. Reoperation. Time Factors. Treatment Outcome. Vimentin / analysis

  • Genetic Alliance. consumer health - Astroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18280055.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents, Alkylating; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / MIB-1 antibody; 0 / Vimentin; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


16. Holzmeister R, Schindler C, Aichholzer M, Pichler J, Trenkler J, Spiegl K, Hammer J: [Intracerebrally localized sarcoma NOS--an interdisciplinary challenge]. Strahlenther Onkol; 2007 Jun;183(6):338-43
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intracerebrally localized sarcoma NOS--an interdisciplinary challenge].
  • [Transliterated title] Intrazerebral lokalisiertes Sarkom NOS--eine interdisziplinäre Herausforderung.
  • Therapeutic guidelines do not exist.
  • CASE REPORT: A 28-year-old female patient presented with a tumor in the postcentral region of the left parietal lobe (Figures 1 and 2).
  • The specimen could not be categorized into a common tumor entity and was classified as sarcoma NOS.
  • Due to the rapid tumor growth irradiation with CT-aided treatment planning (Figure 6) has been started immediately afterwards.
  • RESULT: 2 weeks after treatment, the patient presented with a noticeable tumor regression (magnetic resonance imaging; Figures 7 to 9).
  • She developed pulmonary metastases.
  • A partial remission could be achieved by systemic chemotherapy.
  • CONCLUSION: In cases of intracerebrally localized sarcomas NOS, the earliest possible start of radiotherapy after surgery seems useful because of the noticed radiosensitivity of these tumors.
  • In regard of the local control, this tumor entity shows a documented excellent response to radiotherapy.
  • Interdisciplinary cooperation is mandatory to enhance the diagnostic process, the treatment decisions, and the results.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Cranial Irradiation. Neoplasms, Multiple Primary / radiotherapy. Neurofibrosarcoma / radiotherapy. Parietal Lobe. Patient Care Team
  • [MeSH-minor] Adult. Combined Modality Therapy. Cooperative Behavior. Fatal Outcome. Female. Humans. Lung Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant. Retreatment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520189.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D, Hadani M, Ram Z: Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg; 2004 Mar;100(3):472-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study.
  • OBJECT: A minority of patients with recurrent glioblastomas multiforme (GBMs) responds to systemic chemotherapy.
  • The patients were observed daily by performing diffusion-weighted (DW) magnetic resonance (MR) imaging to assess the convective process and routine diagnostic MR imaging to identify the tumor response.
  • Effective convection was determined by the progression of the hyperintense signal within the tumor on DW MR images, which corresponded to a subsequent lytic tumor response displayed on conventional MR images.
  • The antitumor effect was confirmed by one biopsy and three en bloc resections of tumors, which showed a complete response, and by one tumor resection, which demonstrated a partial response.
  • Lack of convection and a poor tumor response was associated with leakage of the convected drug into the subarachnoid space, ventricles, and cavities formed by previous resections, and was seen in tumors containing widespread necrosis.
  • CONCLUSIONS: On the basis of our data we suggest that CED of paclitaxel in patients with recurrent malignant gliomas is associated with a high antitumor response rate, although it is associated with a significant incidence of treatment-associated complications.
  • Diffusion-weighted MR images may be used to predict a response by demonstrating the extent of convection during treatment.
  • Optimization of this therapeutic approach to enhance its efficacy and reduce its toxicity should be explored further.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Convection. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Diffusion Magnetic Resonance Imaging. Dose-Response Relationship, Drug. Female. Frontal Lobe / pathology. Frontal Lobe / surgery. Glioblastoma / drug therapy. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Male. Middle Aged. Parietal Lobe / pathology. Parietal Lobe / surgery. Prospective Studies. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15035283.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


18. Kanamori M, Kumabe T, Watanabe M, Tominaga T: Anaplastic astrocytoma and anaplastic oligodendroglioma occurring 6 years after subtotal resection of a central neurocytoma. Case report. J Neurosurg; 2007 Jul;107(1):185-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors present the case of a 51-year-old man who presented with an anaplastic astrocytoma and anaplastic oligodendroglioma that developed 6 years after subtotal resection of a central neurocytoma in his right lateral ventricle.
  • He had received neither radiation therapy nor chemotherapy after the original resection.
  • On readmission, neuroimaging revealed a mass in the right parietal lobe and a diffuse lesion in the right temporal lobe, insula, and corona radiata.
  • Histological examination revealed anaplastic oligodendroglioma in the parietal lobe and anaplastic astrocytoma in the insula.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / surgery. Oligodendroglioma / pathology
  • [MeSH-minor] Cell Transformation, Neoplastic. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Time Factors


19. Brown HG, Whiting DM, Prostko ER, Fox KR, Zhang J: January 2001: A 37 year old man with a history of Hodgkin's disease. Brain Pathol; 2001 Jul;11(3):387-8; 393
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both the primary tumor in the lymph node biopsy and the metastatic brain tumor showed similar histopathology and a immunohistochemical profile typical for Hodgkin's Disease.
  • After chemotherapy, there are no signs of recurrence or systemic disease on follow-up for five months.
  • [MeSH-major] Hodgkin Disease / radionuclide imaging. Parietal Lobe / radionuclide imaging
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Humans. Male. Neoplasm Proteins / analysis. Reed-Sternberg Cells / chemistry. Reed-Sternberg Cells / pathology. Syncope / etiology. Tomography, Emission-Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11414479.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


20. Sasani M, Oktenoglu T, Ozer AF, Sarioglu AC: Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature. Pediatr Neurosurg; 2007;43(2):149-54
Genetic Alliance. consumer health - Rhabdoid tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant supratentorial atypical teratoid/rhabdoid tumor presentation: a case of a five-year-old child with favorable outcome and review of the literature.
  • Atypical teratoid/rhabdoid tumor of the central nervous system is a highly malignant neoplasm and that usually arises in the posterior fossa, survival from this is frequently poor.
  • We present a unique case in a 21-month-old girl who had an atypical teratoid/rhabdoid tumor with cystic components located in the right fronto-parietal lobe.
  • The patient underwent radical surgical intervention followed by chemotherapy.
  • Two years later at the last follow-up visit, there was no evidence of a tumor relapse on MRI, and the examination was symptom free.
  • It is possible the favorable outcome of the patient resulted from a rapid diagnosis, prompt management, radical surgical intervention and aggressive chemotherapy.
  • [MeSH-major] Frontal Lobe / surgery. Parietal Lobe / surgery. Rhabdoid Tumor / surgery. Supratentorial Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Actins / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / analysis. Humans. Infant. Keratins / analysis. Magnetic Resonance Imaging. Microsurgery. Mitotic Index. Necrosis. Neurologic Examination. Vimentin / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17337931.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 14
  •  go-up   go-down


21. Schmid I, Stachel D, Graubner UB, Elsner R, Schulze S, Pöllinger B, Goetz C, Haas RJ: [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature]. Klin Padiatr; 2005 May-Jun;217(3):153-7
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Supratentorial primitive neuroectodermal tumor: a single center experience and comparison with the literature].
  • [Transliterated title] Supratentorieller primitiver neuroektodermaler Tumor: Erfahrungen in einem Zentrum im Vergleich zur Literatur.
  • All had craniospinal irradiation and chemotherapy according to the HIT-91 protocol.
  • The two children with incomplete resection died due to tumor progression after 7 and 10 months.
  • Two of the 4 children with complete tumor resection had local relapses 8 months after diagnosis and died after 14 and 18 months.
  • One child had a diffuse meningeal relapse 12 months after diagnosis.
  • Despite (high-dose) systemic chemotherapy and intraventricular mafosfamide, he died 21 months after diagnosis due to tumor although remission could be achieved.
  • Only one child is still in remission 86 months after diagnosis.
  • [MeSH-major] Brain Neoplasms. Cerebellar Nuclei. Corpus Callosum. Frontal Lobe. Neuroectodermal Tumors. Occipital Lobe. Parietal Lobe. Temporal Lobe. Thalamus
  • [MeSH-minor] Brain Stem Neoplasms / secondary. Cerebellar Neoplasms / mortality. Cerebellar Neoplasms / surgery. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Humans. Male. Mesencephalon. Neoplasm Recurrence, Local. Prognosis. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - Supratentorial primitive neuroectodermal tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858707.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Alexiou GA, Moschovi M, Stefanaki K, Prodromou C, Sfakianos G, Prodromou N: Malignant progression of a pleomorphic xanthoastrocytoma in a child. Neuropediatrics; 2010 Aug;41(2):69-71
Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) is a recently recognized rare cerebral neoplasm that predominantly affects young patients.
  • Radiological investigation revealed a lesion in the right parietal-occipital lobe.
  • 1 year later follow-up magnetic resonance imaging (MRI) revealed tumor relapse.
  • The patient received radiotherapy and 9 months later on follow-up MRI a new tumor recurrence was noted.
  • A third craniotomy was performed and the tumor removed.
  • The patient was referred to the oncology department and received chemotherapy with temozolamide.
  • 8 months later the patient was stable without tumor recurrence.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Brain Neoplasms / physiopathology. Glioblastoma / diagnosis
  • [MeSH-minor] Child, Preschool. Disease Progression. Gadolinium. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart.New York.
  • (PMID = 20799153.001).
  • [ISSN] 1439-1899
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] AU0V1LM3JT / Gadolinium
  •  go-up   go-down


23. Kurul S, Cakmakçi H, Dirik E, Kovanlikaya A: Schilder's disease: case study with serial neuroimaging. J Child Neurol; 2003 Jan;18(1):58-61
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The disease often mimics intracranial neoplasm or abscess.
  • Cranial computed tomography and magnetic resonance imaging (MRI) showed large lesions in the subcortical white matter of the occipital and parietal lobes of both hemispheres that were indistinguishable from an abscess.
  • A diagnosis of acute disseminated encephalomyelitis was then suspected.
  • The patient had a dramatic clinical response to corticosteroid therapy.
  • [MeSH-major] Diffuse Cerebral Sclerosis of Schilder / diagnosis. Magnetic Resonance Imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Administration, Oral. Adrenal Cortex Hormones / administration & dosage. Brain Abscess / diagnosis. Child. Corpus Callosum / pathology. Dominance, Cerebral / physiology. Dose-Response Relationship, Drug. Drug Administration Schedule. Encephalomyelitis, Acute Disseminated / diagnosis. Encephalomyelitis, Acute Disseminated / drug therapy. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Methylprednisolone / administration & dosage. Occipital Lobe / pathology. Optic Neuritis / diagnosis. Optic Neuritis / drug therapy. Parietal Lobe / pathology

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12661940.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


24. Bini A, Ansaloni L, Grani G, Grazia M, Pagani D, Stella F, Bazzocchi R: Pulmonary blastoma: report of two cases. Surg Today; 2001;31(5):438-42
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Physical examination revealed slightly significant findings, chest radiographs showed a large pulmonary mass, confirmed by computed tomography, and bronchoscopic biopsies were not diagnostic.
  • A left and right inferior lobectomy was performed and a diagnosis of CPBP was confirmed by histological examination.
  • In the first patient, local recurrence with multiple bilateral lung metastases was found 6 months later and despite chemotherapy, he died of respiratory failure 1 year after his operation.
  • In the second patient, a subcutaneous metastasis was found in the right subscapular region 2 months later, and a cerebral metastasis in the right posterior parietal lobe 4 months later.
  • We conclude that more aggressive and multidisciplinary treatment should be adopted for CBPB, and because of its low incidence, it is important to unify individual experiences in a central registry to gather as much information as possible regarding the biological and clinical features of this unusual disease.
  • [MeSH-minor] Aged. Fatal Outcome. Hemoptysis / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Prognosis. Smoking / adverse effects

  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11381509.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Hadjipanayis CG, Kondziolka D, Gardner P, Niranjan A, Dagam S, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary. J Neurosurg; 2002 Jul;97(1):56-64
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pilocytic astrocytomas when multimodal therapy is necessary.
  • OBJECT: The goal of this study was to examine the role of stereotactic radiosurgery in the treatment of patients with recurrent or unresectable pilocytic astrocytomas.
  • METHODS: During a 13-year interval, 37 patients (median age 14 years) required multimodal treatment of recurrent or unresectable pilocytic astrocytomas.
  • Tumors involved the brainstem in 18 patients, cerebellum in three, thalamus in five, temporal lobe in four, and parietal lobe in two, as well as the hypothalamus, optic tract, corpus callosum, insular cortex, and third ventricle in one patient each.
  • Diagnosis was confirmed with the aid of stereotactic biopsy in 12 patients, open biopsy in five, partial resection in eight, and near-total resection in 12.
  • Multimodal treatment included fractionated radiation therapy in 10 patients, stereotactic intracavitary irradiation of tumor in four, chemotherapy in two, cyst drainage in six, ventriculoperitoneal shunt placement in three, and additional cytoreductive surgery in four.
  • Tumor volumes varied from 0.42 to 25 cm3.
  • The median radiosurgical dose to the tumor margin was 15 Gy (range 9.6-22.5 Gy).
  • After radiosurgery, serial imaging demonstrated complete tumor resolution in 10 patients, reduced tumor volume in eight, stable tumor volume in seven, and delayed tumor progression in 12.
  • No procedure-related death was encountered.
  • Thirty-three (89%) of 37 patients are alive at a median follow-up period of 28 months after radiosurgery and 59 months after diagnosis.
  • Three patients died of local tumor progression.
  • Despite the favorable histological characteristics and prognosis usually associated with this neoplasm, an adverse location, recurrence, or progression of this disease requires alternative therapeutic approaches such as radiosurgery.
  • [MeSH-major] Astrocytoma / surgery. Astrocytoma / therapy. Brain Stem Neoplasms / surgery. Brain Stem Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Biopsy. Child. Child, Preschool. Cisplatin / administration & dosage. Combined Modality Therapy. Cysts / surgery. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Prognosis. Radiotherapy / adverse effects. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12134933.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF, Oncodiagosis panel, 2002 RSNA Scientific Assembly: Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess. Radiographics; 2003 Nov-Dec;23(6):1591-611
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess.
  • [MeSH-major] Brain Abscess / diagnosis. Brain Neoplasms / diagnosis. Cysts / diagnosis. Frontal Lobe. Magnetic Resonance Imaging. Parietal Lobe
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Fatal Outcome. Glioblastoma / drug therapy. Glioblastoma / radiotherapy. Glioblastoma / surgery. Humans. Male. Middle Aged. Quinazolines / therapeutic use. Radiotherapy, Adjuvant. Radiotherapy, Conformal

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14635616.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down






Advertisement